ABOUT K
ACADEMICS
ADMISSION
ALUMNI RELATIONS
GIVING TO K
NEWS & EVENTS
STUDENT LIFE
HORNET HIVE
ATHLETICS
SITEMAP
WEBMAIL
    • Login
    View Item 
    •   DSpace Home
    • Academic Departments, Programs, and SIPs
    • Biology
    • Biology Senior Individualized Projects
    • View Item
    •   DSpace Home
    • Academic Departments, Programs, and SIPs
    • Biology
    • Biology Senior Individualized Projects
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Bortezomib Synergizes with DFMO to Inhibit Neuroblastoma Cell Proliferation via Reversal of the LIN28/Let-7 Axis

    Thumbnail
    View/Open
    Maria-RichSIP.pdf (1.170Mb)
    Date
    2015
    Author
    Rich, Maria E.
    Metadata
    Show full item record
    Abstract
    As scientists and physicians continue to search for better and long-term treatment for cancer, greater focus has recently been placed on molecular guided therapy and the targeting of cancer stem cells (CSCs). One pathway associated with targeting CSCs is the LIN28/Let-7 pathway due to the inductive role of LIN28 in stem cell growth and glycolytic metabolism. LIN28 protein is characteristically overexpressed and correlates with poor outcome in many different malignancies including Neuroblastoma (NB), the most common extracranial solid pediatric tumor. Therefore, drugs that target the LIN28/Let-7 axis could be beneficial in treating NB patients by targeting CSCs and preventing relapse of disease. This study investigated the drug combination therapy of Difluoromethylornithine (DFMO)—an inhibitor of ornithine decarboxylase—coupled with bortezomib—a proteasome inhibitor—as a new therapeutic upstream target of LIN28/Let-7 pathway and glycolytic metabolism. Cell proliferation assays and isobologram experiments suggest synergistic cytotoxicity of the drug combination in two NB cell lines. Western blot analysis demonstrated regulation of the Lin28/Let-7 pathway with inhibition of LIN28 protein expression. Decrease in ATP-per-cell when treated with combination drug therapy suggests inhibition of glycolytic metabolic activity in NB cells. In vivo studies showed a trend in decreased tumor size for combination treatment compared to control or DFMO-treated mice. Results indicate that DFMO and bortezomib act synergistically to inhibit glycolytic metabolism via the LIN28/Let-7 pathway and prevent NB CSC survival. Given the current lack of effective treatments and the high incidence of relapse and metastatic disease for patients, bortezomib in combination with DFMO offers a potential new therapeutic treatment for children with NB.
    URI
    http://hdl.handle.net/10920/29514
    Collections
    • Biology Senior Individualized Projects [1405]

    DSpace software copyright © 2002-2013  Duraspace
    Contact Us | Send Feedback
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesThis CollectionBy Issue DateAuthorsTitles

    My Account

    Login

    DSpace software copyright © 2002-2013  Duraspace
    Contact Us | Send Feedback
     

     

    K logo
    Kalamazoo College
    1200 Academy Street
    Kalamazoo Michigan 49006-3295
    USA
    Info 269-337-7000
    Admission 1-800-253-3602
    ABOUT K
    ACADEMICS
    ADMISSION
    ALUMNI RELATIONS
    GIVING TO K
    NEWS & EVENTS
    STUDENT LIFE

    Sitemap
    Map and Directions
    Contacts
    Directories
    Nondiscrimination Policy
    Consumer Information
    Official Disclaimer
    Search this site





    Academic Calendars
    Apply
    Bookstore
    Crisis Response
    Employment
    Library
    Registrar